Navigation Links
FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer
Date:6/15/2009

BOSTON, June 15 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough PET molecular imaging agents, announced that it will present Phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled PET tracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto.

The results of this study will be presented by Dr. David Elmaleh, Director of Contrast Media Chemistry at the Massachusetts General Hospital and Associate Professor at Harvard Medical School, at the "New Tracers, New Agents and New Stressors" scientific session on Tuesday, June 16, 2009, from 1:15 p.m. - 1:30 p.m. (EDT).

BFPET is 18-F labeled tetraphenylphosphonium compound, designed to assess mitochondrial damage and myocardial perfusion. Myocardial perfusion imaging is a standard test to assess coronary artery disease (CAD) with more than 9 million Americans undergoing the test annually.

About FluoroPharma

FluoroPharma is a molecular imaging company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing three proprietary products for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target either the myocardial cells within the heart or inflamed plaques within the coronary arteries. www.fluoropharma.com

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or impli
'/>"/>

SOURCE FluoroPharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FluoroPharma Obtains US Patent for Imaging Cardiovascular Plaque using FDG
2. FluoroPharma Inc. Expands Technology Platform to Include Agents for Alzheimers Disease (AD)
3. Michael Simmons, DMD presented a poster at the American Academy of Dental Sleep Medicine Meeting
4. WebMD to Present at Jefferies 3rd Annual Healthcare Conference
5. Alexzas Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference
6. First-Ever Standardized Scales to Measure the Skins Aging Process Are Presented at THE Aesthetic Show
7. Isis Pharmaceuticals to Present at Jefferies 3rd Annual Healthcare Conference
8. IPC The Hospitalist Company, Inc. to Present at Jefferies 3rd Annual Healthcare Conference
9. NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep Societies
10. Kensey Nash to Present at the Jefferies 3rd Annual Healthcare Conference
11. Latest trinational report presents most complete picture of North American industrial pollution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 The family of a Vermont ... a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his ... LLP reports. According to the complaint, which was filed ... on July 25th, the decedent had been taking Xarelto ... brain bleed that ultimately led to his death on ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
(Date:7/30/2014)... The Ehlers-Danlos National Foundation (EDNF) is pleased ... Chack will serve as chair. The board was voted ... Learning Conference in Houston, Texas July 10-12. , ... of us. From the rollout of the first EDNF ... Baltimore Medical Center to our September physicians conference to ...
(Date:7/30/2014)... Children’s Hospital of Michigan Foundation and Kohl’s invite ... to 7 p.m. Wednesday, August 6 at the Kohl’s ... 48152). The event will feature Detroit Red Wings defenseman ... and local public safety officials. Kohl’s will present a ... Foundation. , The gift supports Kohl’s Injury Prevention ...
(Date:7/30/2014)... York, NY (PRWEB) July 30, 2014 Frozen ... Women are more likely to develop this nasty condition which ... and 60, and can last up to two and half ... known as frozen shoulder, and with good reason: it can ... your shirt — that is, if you aren't in too ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Ehlers-Danlos National Foundation Announces New Leadership 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4Health News:Good News for Diabetics Suffering from Frozen Shoulder 2Health News:Good News for Diabetics Suffering from Frozen Shoulder 3Health News:Good News for Diabetics Suffering from Frozen Shoulder 4
... a PET scan may interfere with the results seen, says ... emission tomography (PET) or computed tomography (CT) scan is done ... evaluate the effect of treatment on an already diagnosed malignant ... in the body that can be traced with the help ...
... have reportedly succeeded in generating sperm// and ovarian cells ... for Stem Cell Biology in Sheffield said that "the ... sperm and eggs to use in assisted conception treatments". ... with infertility. This research will allow embryonic stem cells ...
... processed meat can increase your chance of having colorectal ... the National Cancer Institute. ,Colon and rectum together ... cancer is also called colorectal cancer. Cancer of the ... malignant cells within the lining of colon or rectum. ...
... in schizophrenic patients with the help of seroquel ... is a chronic severe disabling mental illness. Some ... seen or heard, feelings of being persecuted, becoming ... symptomatically, but only one in five patients have ...
... Researchers had been able to find out why the diabetes ... University of Utah had found that the drug TZDs activates ... This is situated in the collecting duct of the kidney. ... in the body and causes edema. ,TZD drugs are ...
... inflammations of the gum may increase the risk of ... early in life. ,According to a research study ... Conference on Prevention of Dementia held in US, periodontal ... people. ,Alzheimer’s disease affects the brain cells and ...
Cached Medicine News:
(Date:7/30/2014)... 2014  Cepheid (Nasdaq: CPHD ) ... Premier will end on September 30, 2014.  Customers ... able to continue their relationship with Cepheid through ... and ROi, in addition to the recently announced ... "Cepheid has always recognized and supported the ...
(Date:7/30/2014)... CUPERTINO, Calif. , July 30, 2014 ... ) second quarter 2014 financial results press release, you ... will be broadcast live over the internet on Thursday, ... pm Pacific Time). A live audio webcast ... homepage at http://www.durect.com and clicking "Investor Relations."  ...
(Date:7/30/2014)... , July 30, 2014 The ... Care Pharmacy (AMCP) last evening expressed support for ... the Joint Commission of Pharmacy Practitioners (JCPP).  As ... organizations over a two-year period to develop a ... pharmacists.  "Pharmacists are fast becoming ...
Breaking Medicine Technology:Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2
... SIPP International Industries Inc. (OTCBB: SIPN), ... hospitality and medical technology industries announced today that they ... Japanese Consulting firm based in Osaka Japan. Upon completion ... residual revenues within three months.  FVJ ...
... Jan. 17, 2012 Bayer HealthCare today announced latest ... the Phase III CORRECT ( Co lo r ectal ... ebo after failure of standard t herapy) trial. ... improvement in overall survival (OS) by 29% (HR=0.77, p=0.0052, median ...
Cached Medicine Technology:SIPP International Industries, Inc. to Acquire Controlling Interest in FVJ Holdings out of Osaka Japan 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 2Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 3Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 4Phase III Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Thera 5
... parafollicular C-cells of the thyroid gland and ... action of calcitonin is to lower plasma ... in decreased mobilization of calcium from bone ... conditions associated with high levels of bone ...
Calcitonin RIA Kit...
... The Matrix Perimeter utilizes Welch ... a significant breakthrough in visual field ... capabilities, tools to characterize glaucoma and ... Humphrey FDT Perimeter, the Matrix doubles ...
... digital camera system by KARL STORZ, a ... camera systems. Digital Source Sampling technology, applied ... fully digital transfer of information with no ... as well as loss-free data storage on ...
Medicine Products: